+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Tolvaptan Improves the Long-Term Prognosis in Patients With Congestive Heart Failure With Preserved Ejection Fraction as Well as in Those With Reduced Ejection Fraction



Tolvaptan Improves the Long-Term Prognosis in Patients With Congestive Heart Failure With Preserved Ejection Fraction as Well as in Those With Reduced Ejection Fraction



International Heart Journal 57(5): 600-606



Tolvaptan (TLV), an arginine vasopressin type 2 antagonist, has been shown to play a role in ameliorating symptomatic congestion and normalizing diluted hyponatremia in patients with congestive heart failure (HF). However, most evidence was derived from patients with HF with reduced ejection fraction (HFrEF), and the clinical efficacy of TLV in patients with HF with preserved ejection fraction (HFpEF) remains uncertain. In this study, we retrospectively enrolled 60 in-hospital patients with stage D HF, who had received TLV to treat symptomatic congestion at our institute between 2011 and 2013. As a control group, we also enrolled 60 background-matched HF patients who did not receive TLV therapy. Patients with HFpEF (n = 29), whose left ventricular ejection fraction was > 45%, had higher age and a lower urine aquaporin-2 level relative to the plasma arginine vasopressin concentration compared with those with HFrEF (n = 91). TLV therapy significantly reduced the 2-year readmission rates in both the HFrEF and HFpEF populations (P < 0.05 for both), indicating that TLV therapy may improve the long-term prognosis not only in patients with HFrEF but also in those with HFpEF.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 059140296

Download citation: RISBibTeXText

PMID: 27581675

DOI: 10.1536/ihj.16-023


Related references

Characteristics and long-term prognosis of patients with heart failure and mid-range ejection fraction compared with reduced and preserved ejection fraction: a systematic review and meta-analysis. Esc Heart Failure 5(4): 685-694, 2018

Heart failure with preserved ejection fraction has a better long-term prognosis than heart failure with reduced ejection fraction in old patients in a 5-year follow-up retrospective study. International Journal of Cardiology 232: 86-92, 2017

Short and long-term prognostic value of hyponatremia in heart failure with preserved ejection fraction versus reduced ejection fraction: An analysis of the Korean Acute Heart Failure registry. International Journal of Cardiology 248: 239-245, 2017

Congestive heart failure in the elderly: comparison between reduced ejection fraction and preserved ejection fraction. Journal of Cardiology 59(2): 215-219, 2012

Comparison of β-blocker effectiveness in heart failure patients with preserved ejection fraction versus those with reduced ejection fraction. Journal of Cardiac Failure 19(2): 73-79, 2013

Different implication of elevated B-type natriuretic peptide level in patients with heart failure with preserved ejection fraction and in those with reduced ejection fraction. Echocardiography 32(4): 623-629, 2015

Thromboembolisms in atrial fibrillation and heart failure patients with a preserved ejection fraction (HFpEF) compared to those with a reduced ejection fraction (HFrEF). Heart and Vessels 33(4): 403-412, 2017

Long term prognosis of chronic heart failure: reduced vs preserved left ventricular ejection fraction. Circulation Journal 73(1): 92-99, 2008

Effects of exercise on left ventricular systolic and diastolic properties in patients with heart failure and a preserved ejection fraction versus heart failure and a reduced ejection fraction. Circulation. Heart Failure 6(3): 508-516, 2013

Comparable effect of tolvaptan in heart failure patients with preserved or reduced ejection fraction. Clinical and Experimental Hypertension 2019: 1-8, 2019

Comparison of the reliability of E/E' to estimate pulmonary capillary wedge pressure in heart failure patients with preserved ejection fraction versus those with reduced ejection fraction. International Journal of Cardiovascular Imaging 31(8): 1497-1502, 2016

Comparison of characteristics and outcomes of patients with heart failure preserved ejection fraction versus reduced left ventricular ejection fraction in an urban cohort. American Journal of Cardiology 113(4): 691-696, 2014

Longitudinal changes in ejection fraction in heart failure patients with preserved and reduced ejection fraction. Circulation. Heart Failure 5(6): 720-726, 2013

Effective blood hemoglobin level to predict prognosis in heart failure with preserved left ventricular ejection fraction: results of the Japanese heart failure syndrome with preserved ejection fraction registry. Heart and Vessels 2019, 2019

Prognosis for patients with heart failure with preserved ejection fraction. Is it the same as low ejection fraction?. Revista Espanola de Cardiologia 64(8): 646-648, 2011